Akebia Stock Analysis

The current indifference towards the small price fluctuations of Akebia Therapeutics could raise concerns from investors as the firm it trading at a share price of 0.0 on very low momentum in volume. The company executives did not add any value to Akebia Therapeutics investors in June. However, most investors can still diversify their portfolios with Akebia Therapeutics to hedge their inherited risk against high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently very low. The very small Stock volatility is a good signal to investors with longer-term investment horizons.
Check out Trending Equities.

Search Stock Analysis 

 
Refresh
The Akebia Therapeutics stock analysis report makes it easy to digest most publicly released information about Akebia Therapeutics and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Akebia Stock analysis module also helps to analyze the Akebia Therapeutics price relationship with some important fundamental indicators such as market cap and management efficiency.

Akebia Stock Analysis Notes

About 67.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.96. Some equities with similar Price to Book (P/B) outperform the market in the long run. Akebia Therapeutics recorded a loss per share of 2.71. The entity had not issued any dividends in recent years. Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of renal therapeutics for patients with kidney diseases. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts. Akebia Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 379 people. For more info on Akebia Therapeutics please contact John Butler at 617 871-2098 or go to www.akebia.com.

Akebia Therapeutics Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Akebia Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Akebia Therapeutics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Akebia Therapeutics is not yet fully synchronised with the market data
Akebia Therapeutics has some characteristics of a very speculative penny stock
Akebia Therapeutics has high likelihood to experience some financial distress in the next 2 years
The company reported the previous year's revenue of 259.13 M. Net Loss for the year was (392.29 M) with profit before overhead, payroll, taxes, and interest of 12.86 M.
Akebia Therapeutics currently holds about 272.76 M in cash with (91.55 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.7.
Akebia Therapeutics has a poor financial position based on the latest SEC disclosures
Roughly 67.0% of the company shares are held by institutions such as insurance companies

Akebia Therapeutics Upcoming and Recent Events

Earnings reports are used by Akebia Therapeutics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Akebia Therapeutics previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report5th of August 2021
Next Earnings Report4th of November 2021
Next Fiscal Quarter End30th of June 2021
Next Fiscal Year End24th of February 2022
Last Quarter Report31st of March 2021
Last Earning Announcement30th of June 2020

Akebia Therapeutics SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Akebia Therapeutics prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Akebia Therapeutics investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Akebia Therapeutics specific information freely available to individual and institutional investors to make a timely investment decision.
12th of July 2021
Unclassified Corporate Event
View
3rd of June 2021
Submission of Matters to a Vote of Security Holders
View
1st of June 2021
Financial Statements and Exhibits. Other Events. Regulation FD Disclosure
View
10th of May 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
30th of March 2021
Financial Statements and Exhibits. Other Events. Regulation FD Disclosure
View
25th of February 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
18th of February 2021
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
17th of February 2021
Entry into a Material Definitive Agreement
View

Akebia Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 422.7 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Akebia Therapeutics's market, we take the total number of its shares issued and multiply it by Akebia Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Akebia Profitablity

Akebia Therapeutics' profitability indicators refer to fundamental financial ratios that showcase Akebia Therapeutics' ability to generate income relative to its revenue or operating costs. If, let's say, Akebia Therapeutics is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Akebia Therapeutics' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Akebia Therapeutics' profitability requires more research than a typical breakdown of Akebia Therapeutics' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of (151.39) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (64.84) %, which suggests for every $100 dollars of sales, it generated a net operating loss of -0.65.
Last ReportedProjected for 2021
Return on Investment(92.43) (99.73) 
Return on Average Assets(0.54) (0.58) 
Return on Average Equity(1.15) (1.18) 
Return on Invested Capital(1.91) (2.06) 
Return on Sales(1.27) (1.37) 

Management Efficiency

The entity has return on total asset (ROA) of (14.83) % which means that it has lost $14.83 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (128.57) %, meaning that it created substantial loss on money invested by shareholders. Akebia Therapeutics management efficiency ratios could be used to measure how well akebia therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of July 30, 2021, Return on Investment is expected to decline to -99.73. In addition to that, Return on Average Assets is expected to decline to -0.58. Akebia Therapeutics Goodwill and Intangible Assets are projected to decrease significantly based on the last few years of reporting. The past year's Goodwill and Intangible Assets were at 199.22 Million. The current year Total Assets Per Share is expected to grow to 4.46, whereas Total Assets are forecasted to decline to about 555.6 M.
Last ReportedProjected for 2021
Book Value per Share 1.79  1.93 
Enterprise Value over EBIT(1.00) (1.08) 
Enterprise Value over EBITDA(0.98) (1.06) 
Price to Book Value 1.63  2.12 
Tangible Assets Book Value per Share 3.21  3.30 
Enterprise Value335.5 M392.4 M
Tangible Asset Value444.9 M391 M

Akebia Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Akebia Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Akebia Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Akebia Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Steven Gilman over a month ago via Macroaxis 
Sale by Steven Gilman of 4567 shares of Akebia Therapeutics
Wolf Myles over a month ago via Macroaxis 
Acquisition by Wolf Myles of 20100 shares of Akebia Therapeutics subject to Rule 16b-3
Dell Faulkingham over three months ago via Macroaxis 
Sale by Dell Faulkingham of 952 shares of Akebia Therapeutics
Dell Faulkingham over three months ago via Macroaxis 
Acquisition by Dell Faulkingham of 9152 shares of Akebia Therapeutics subject to Rule 16b-3
Steven Burke over three months ago via Macroaxis 
Acquisition by Steven Burke of 120000 shares of Akebia Therapeutics subject to Rule 16b-3
Zumwalt Leanne M over three months ago via Macroaxis 
Acquisition by Zumwalt Leanne M of 80200 shares of Akebia Therapeutics subject to Rule 16b-3
Cotreau Violetta over six months ago via Macroaxis 
Akebia Therapeutics exotic insider transaction detected
Jodie Morrison over six months ago via Macroaxis 
Acquisition by Jodie Morrison of 20100 shares of Akebia Therapeutics subject to Rule 16b-3
Spellman David A over a year ago via Macroaxis 
Acquisition by Spellman David A of 280000 shares of Akebia Therapeutics subject to Rule 16b-3
Cynthia Smith over a year ago via Macroaxis 
Acquisition by Cynthia Smith of 20100 shares of Akebia Therapeutics subject to Rule 16b-3
Cynthia Smith over a year ago via Macroaxis 
Acquisition by Cynthia Smith of 13700 shares of Akebia Therapeutics subject to Rule 16b-3
Dell Faulkingham over a year ago via Macroaxis 
Sale by Dell Faulkingham of 6426 shares of Akebia Therapeutics

Akebia Therapeutics Technical and Predictive Indicators

Be your own money manager

As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Akebia Therapeutics to your portfolios without increasing risk or reducing expected return.

Did you try this?

Run Financial Widgets Now

   

Financial Widgets

Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
All  Next Launch Module
Check out Trending Equities. Note that the Akebia Therapeutics information on this page should be used as a complementary analysis to other Akebia Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.

Other Tools for Akebia Stock

When running Akebia Therapeutics price analysis, check to measure Akebia Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Akebia Therapeutics is operating at the current time. Most of Akebia Therapeutics' value examination focuses on studying past and present price action to predict the probability of Akebia Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Akebia Therapeutics' price. Additionally, you may evaluate how the addition of Akebia Therapeutics to your portfolios can decrease your overall portfolio volatility.
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Go
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Go
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Go
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Go